NCT07150403 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07150403
Title	A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Federation Francophone de Cancerologie Digestive
Indications	colorectal cancer
Therapies	Fluorouracil + Fruquintinib + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Fruquintinib + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	FRA

Additional content available in CKB BOOST